Herpes Simplex Virus 1+2 IgG

This panel measures antibodies against six different viruses (EBV, CMV, HSV-1, HSV-2, HHV-6, VZV) that are involved in different inflammatory autoimmune diseases, chronic fatigue syndrome or myalgic encephalitis, neurodegenerative disorders such as Alzheimer’s and Parkinson’s, and neurological disorders such as Guillain-Barré syndrome and multiple sclerosis. Reactivation of these viruses is a major driver in increasing the severity of symptoms in patients with COVID-19. The test confirms immunological memory against Varicella zoster (VZV), the causative agent for shingles.

This panel measures antibodies against seven different viruses (EBV, CMV, HSV-1, HSV-2, HHV-6, VZV, measles) that are involved in different inflammatory autoimmune diseases, chronic fatigue syndrome or myalgic encephalitis, neurodegenerative disorders such as Alzheimer’s and Parkinson’s, and neurological disorders such as Guillain-Barré syndrome and multiple sclerosis. Reactivation of these viruses is a major driver in increasing the severity of symptoms in patients with COVID-19. The test confirms immunological memory against Varicella zoster (VZV), the causative agent for shingles, and against Rubeola, the causative agent for measles.

This screen detects chronic and ongoing infection with four major herpes viruses (EBV, CMV, HSV-1, HSV-2) that are involved in different inflammatory autoimmune and neurodegenerative disorders such as Alzheimer’s and Parkinson’s, and neurological disorders such as Guillain-Barré syndrome and multiple sclerosis. Reactivation of these viruses is a major driver in increasing the severity of symptoms in patients with COVID-19.

The test is used to determine the absence or presence of IgG and IgM antibodies to HSV-1 and HSV-2.